search
Back to results

Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)

Primary Purpose

Meniscal Tear

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bone marrow venting procedure (BMVP)
Platelet Rich Plasma (PRP)
Sponsored by
University of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Meniscal Tear

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Age 16 or older
  2. Medial, lateral, vertical longitudinal, oblique, or radial meniscal tear
  3. Complex tears may be included at the discretion of the site investigator if patient has one of tear patterns listed in inclusion criteria 2 as the most predominant finding
  4. No other concomitant procedure unless one of the following:

    • Chondroplasty
    • Synovectomy
    • Loose body removal
    • "Contralateral" menisectomy (i.e. medial meniscus repair with a lateral menisectomy or lateral meniscus repair with a medial menisectomy) would be permitted for inclusion
    • Any other procedure that does not include drilling, requires prior approval of the study sponsor for each procedure

Exclusion Criteria

  1. Patients requiring cartilage restorative or repair procedures (i.e. OCD fixation, micro-fracture repair, or others)
  2. Patients with meniscus root tears
  3. Patients undergoing repair for horizontal cleavage tears
  4. Kellgren-Lawrence scale 3>
  5. Patients undergoing lateral release
  6. Ipsilateral chondral lesion with Outerbridge classification of 3-4
  7. Use of prednisone or other steroids, any immunosuppressant, or chemotherapy 1-week before surgery or expected use within six weeks after surgery
  8. Cortisone use within the six weeks prior to surgery
  9. Utilizing worker's compensation at the time of screening
  10. Any previous ligament surgery on the index limb. Any previous meniscal surgery on the index meniscus.
  11. Concomitant ligamentous insufficiency
  12. Inflammatory rheumatic disease or other rheumatic disease
  13. Immune compromised patients (hepatitis, HIV, etc.)
  14. Any nicotine based products within the three months prior to surgery (including cigarettes, cigars, vaping, nicotaine patch, etc)
  15. History of distal femur, proximal tibia, or patellar fracture that was treated operatively
  16. Non English-speaking patients

Sites / Locations

  • University of FloridaRecruiting
  • University of Chicago MedicineRecruiting
  • Wake Forest University Health SciencesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Bone marrow venting procedure (BMVP)

Platelet rich plasma (PRP)

Arm Description

Subjects randomized in the OR to undergo BMVP surgical augmentation

Subjects randomized in the OR to undergo PRP surgical augmentation

Outcomes

Primary Outcome Measures

Promis Physical function CAT lower extremity score
Adaptive questionnaire that takes five minutes or less to complete and helps record how subject injury and recovery from surgery is affecting their normal life.

Secondary Outcome Measures

Re-tear of repair meniscus
Clinically reported (symptomatic) and MRI confirmed via observation of fluid filled tear in the repaired tissue

Full Information

First Posted
February 24, 2021
Last Updated
July 11, 2022
Sponsor
University of Chicago
Collaborators
American Orthopaedic Society for Sports Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04775004
Brief Title
Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)
Official Title
Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 19, 2021 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Chicago
Collaborators
American Orthopaedic Society for Sports Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There are no current or past RCT comparing biologic augments for meniscal repair. There is good data supporting both the use of BMVP of the intercondylar notch and intra-articular PRP injections for augmentation of meniscal repair. However, the effectiveness of these augmentation methods with respect to each other has never been investigated. The knowledge gained will allow us to potentially influence and adapt protocols to treat this particular patient population. Additionally, resources available at our institution provide a supportive framework with which to maintain contact with patients after hospital discharge. These key factors will allow us to perform a robust analysis of this population, to include outcomes measures of function as well as meniscal repair failure and reoperation rate. The proposed interventional aim to compare meniscal repair augmentation methods is novel, as the direct comparison of these outcome measures has not been previously described. Because of the known benefit of biologic augmentation of meniscal repair, the investigators hypothesize that the repair failure rate for both cohorts will be lower than the reported repair failure rate for isolated tears without biologic augmentation; the investigators also hypothesize that BMVP of the intercondylar notch will clinically be significantly better than intra-articular PRP injection. The basis behind this hypothesis is in vivo evidence as well as a small RCT supporting the use of BMVP as augmentation for meniscal repair procedures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meniscal Tear

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
146 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bone marrow venting procedure (BMVP)
Arm Type
Active Comparator
Arm Description
Subjects randomized in the OR to undergo BMVP surgical augmentation
Arm Title
Platelet rich plasma (PRP)
Arm Type
Active Comparator
Arm Description
Subjects randomized in the OR to undergo PRP surgical augmentation
Intervention Type
Other
Intervention Name(s)
Bone marrow venting procedure (BMVP)
Intervention Description
The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
Intervention Type
Other
Intervention Name(s)
Platelet Rich Plasma (PRP)
Intervention Description
The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
Primary Outcome Measure Information:
Title
Promis Physical function CAT lower extremity score
Description
Adaptive questionnaire that takes five minutes or less to complete and helps record how subject injury and recovery from surgery is affecting their normal life.
Time Frame
1-year after meniscus tear operation.
Secondary Outcome Measure Information:
Title
Re-tear of repair meniscus
Description
Clinically reported (symptomatic) and MRI confirmed via observation of fluid filled tear in the repaired tissue
Time Frame
1-year after meniscus tear operation.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Age 16 or older Medial, lateral, vertical longitudinal, oblique, or radial meniscal tear Complex tears may be included at the discretion of the site investigator if patient has one of tear patterns listed in inclusion criteria 2 as the most predominant finding No other concomitant procedure unless one of the following: Chondroplasty Synovectomy Loose body removal "Contralateral" menisectomy (i.e. medial meniscus repair with a lateral menisectomy or lateral meniscus repair with a medial menisectomy) would be permitted for inclusion Any other procedure that does not include drilling, requires prior approval of the study sponsor for each procedure Exclusion Criteria Patients requiring cartilage restorative or repair procedures (i.e. OCD fixation, micro-fracture repair, or others) Patients with meniscus root tears Patients undergoing repair for horizontal cleavage tears Kellgren-Lawrence scale 3> Patients undergoing lateral release Ipsilateral chondral lesion with Outerbridge classification of 3-4 Use of prednisone or other steroids, any immunosuppressant, or chemotherapy 1-week before surgery or expected use within six weeks after surgery Cortisone use within the six weeks prior to surgery Utilizing worker's compensation at the time of screening Any previous ligament surgery on the index limb. Any previous meniscal surgery on the index meniscus. Concomitant ligamentous insufficiency Inflammatory rheumatic disease or other rheumatic disease Immune compromised patients (hepatitis, HIV, etc.) Any nicotine based products within the three months prior to surgery (including cigarettes, cigars, vaping, nicotaine patch, etc) History of distal femur, proximal tibia, or patellar fracture that was treated operatively Non English-speaking patients
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Justin Bell
Phone
773-834-0822
Email
jbell3@bsd.uchicago.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aravind Athiviraham, MD
Organizational Affiliation
University of Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marissa Pazik, MS
Email
pazikmn@ortho.ufl.edu
Facility Name
University of Chicago Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justin Bell
Phone
773-834-0822
First Name & Middle Initial & Last Name & Degree
Aravind Athiviraham, MD
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erica Hartzell, MS
Email
ehartzel@wakehealth.edu
First Name & Middle Initial & Last Name & Degree
Nina Cruz-Diaz
Email
nmcruzdi@wakehealth.edu

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data will not be available to other researchers.

Learn more about this trial

Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)

We'll reach out to this number within 24 hrs